CAJ | 학술논문

目的:观察亚砷酸注射液(三氧化二砷,As2O3)联合吉西他滨和顺铂方案治疗难治性或复发性非霍奇金淋巴瘤(NHL)的有效率.方法:18例难治性或复发性NHL患者 ,男性12例,女性6例,中位年龄 51岁.给予As2O3注射液 10mg/d静脉滴注第1-14天,吉西他滨 1000mg/m2,第 1和第8天,顺铂 25mg/m2第 1-3天,21d为 1个周期.结果:18例患者中完全缓解4例,部分缓解7例,有效率 61.1%.肿瘤中位进展时间(TTP)6.5个月,1年生存率 42.3%.不良反应主要为血液学毒性、肝肾功能损害.结论:亚砷酸注射液联合吉西他滨和顺铂方案是治疗复发或难治性非霍奇金淋巴瘤较为安全、有效的化疗方案.
목적:관찰아신산주사액(삼양화이신,As2O3)연합길서타빈화순박방안치료난치성혹복발성비곽기금림파류(NHL)적유효솔.방법:18례난치성혹복발성NHL환자 ,남성12례,녀성6례,중위년령 51세.급여As2O3주사액 10mg/d정맥적주제1-14천,길서타빈 1000mg/m2,제 1화제8천,순박 25mg/m2제 1-3천,21d위 1개주기.결과:18례환자중완전완해4례,부분완해7례,유효솔 61.1%.종류중위진전시간(TTP)6.5개월,1년생존솔 42.3%.불량반응주요위혈액학독성、간신공능손해.결론:아신산주사액연합길서타빈화순박방안시치료복발혹난치성비곽기금림파류교위안전、유효적화료방안.
Objective:To evaluate the efficacy of a combination of arsenious oxide and gemcitabine plus cisplatin in patients with relapsed or refractory non-Hedgkin's lymphoma.Methods:Eighteen patients (12 males and 6 females) with relapsed or refractory NHL were observed,patients were treated by gemcitabine 1000mg/m2 on d1,8 and cisplatin 25mg/m2 on d1-3.Arsenious oxide 10mg/d infusion,from the first to 14 day,repeated every 21 days.Ressults:Of 18 assessable patients,over all response rate was 61.1%,including 4 complete response and 7 patial response.Median time to progression was 6.5 months,and 1 year survival rate was 42.3% .Toxicity mainly included mylosuppreasion,hepatorenal dysfunction.Conclusion:Arsenious oxide and gemcitabine plus cisplatin chemotherpy regimen is safe and effective for patients with relapsed or refractory non-Hodgkin's lymphoma.